SLC10A2 and metabolic dysfunction-associated steatotic liver disease: In addition, ASBT inhibitors have been shown to protect against the development of MASLD by restoring glucose tolerance and reducing TG levels in the liver in diet-induced MASLD in vivo models [165–167], while clinical trials showed no therapeutic impact [168].